Adenomas from individuals with pathogenic biallelic variants in the MUTYH and NTHL1 genes demonstrate base excision repair tumour mutational signature profiles similar to colorectal cancers, expanding potential diagnostic and variant classification applications.

Autor: Walker R; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia., Joo JE; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia., Mahmood K; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.; Melbourne Bioinformatics, The University of Melbourne, Melbourne, VIC, 3053, Australia., Clendenning M; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia., Como J; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia., Preston SG; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia., Joseland S; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia., Pope BJ; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; Melbourne Bioinformatics, The University of Melbourne, Melbourne, VIC, 3053, Australia., Medeiros ABD; Clinical and Functional Genomics Group, International Research Centre/CIPE, A.C. Camargo Cancer Centre, Sao Paulo, 01508-010, Brazil., Murillo BV; Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, 6008, Australia., Pachter N; Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, 6008, Australia.; Medical School, University of Western Australia, Perth, WA, 6009, Australia.; School of Medicine, Curtin University, Perth, WA, 6845, Australia., Sweet K; Division of Human Genetics, Department of Internal Medicine, College of Medicine, The Ohio State University, Columbus, OH, 43210, USA., Spigelman AD; Hunter Family Cancer Service, Newcastle, NSW, 2298, Australia.; St Vincent's Cancer Genetics Unit, Sydney, NSW, 2290, Australia.; Surgical Professorial Unit, UNSW Clinical School of Clinical Medicine, Sydney, NSW, 2052, Australia., Groves A; Hunter Family Cancer Service, Newcastle, NSW, 2298, Australia., Gleeson M; Hunter Family Cancer Service, Newcastle, NSW, 2298, Australia., Bernatowicz K; Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia., Poplawski N; Adult Genetics Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.; Adelaide Medical School, University of Adelaide, Adelaide, South Australia, Australia., Andrews L; Hereditary Cancer Centre, Prince of Wales Hospital, Randwick, New South Wales, Australia.; School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia., Healey E; Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, Randwick, New South Wales 2031 Australia.; Illawarra Cancer Care Centre, Wollongong Hospital, Wollongong, New South Wales 2500 Australia., Gallinger S; Lunenfeld Tanenbaum Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada., Grant RC; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Win AK; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, VIC, 3053, Australia., Hopper JL; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, VIC, 3053, Australia., Jenkins MA; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.; Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, VIC, 3053, Australia., Torrezan GT; Clinical and Functional Genomics Group, International Research Centre/CIPE, A.C. Camargo Cancer Centre, Sao Paulo, 01508-010, Brazil.; National Institute of Science and Technology in Oncogenomics and Therapeutic Innovation, Sao Paulo 01508-010, Brazil., Rosty C; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.; Envoi Specialist Pathologists, Brisbane, QLD, 4059, Australia.; University of Queensland, Brisbane, QLD, 4072, Australia., Macrae FA; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.; Department of Medicine, The University of Melbourne, Parkville, VIC, 3000, Australia.; Colorectal Medicine and Genetics, The Royal Melbourne Hospital, Parkville, VIC, 3000, Australia., Winship IM; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, 3000, Australia.; Department of Medicine, The University of Melbourne, Parkville, VIC, 3000, Australia., Buchanan DD; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.; Genomic Medicine and Family Cancer Clinic, Royal Melbourne Hospital, Parkville, VIC, 3000, Australia., Georgeson P; Colorectal Oncogenomics Group, Department of Clinical Pathology, The University of Melbourne, Parkville, VIC, 3010, Australia.; University of Melbourne Centre for Cancer Research, Victorian Comprehensive Cancer Centre, Parkville, VIC, 3010, Australia.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Aug 09. Date of Electronic Publication: 2024 Aug 09.

Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer.

Autor: Prior O; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Macarro C; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Navarro V; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Monreal C; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Ligero M; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Garcia-Ruiz A; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Serna G; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Simonetti S; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Braña I; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Vieito M; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Escobar M; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Capdevila J; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Byrne AT; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Dienstmann R; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Toledo R; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Nuciforo P; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Garralda E; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Grussu F; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Bernatowicz K; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.)., Perez-Lopez R; From the Radiomics Group, Vall d'Hebron Institute of Oncology, Carrer de Natzaret 115-117, Barcelona 08035, Spain (O.P., C. Macarro, C. Monreal, M.L., A.G.R., F.G., K.B., R.P.L.); Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (V.N., R.D.); Molecular Pathology Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain (G.S., S.S., P.N.); Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain (I.B., M.V., E.G., J.C.); Molecular Therapeutic Research Unit, Vall d'Hebron Institute of Oncology, Barcelona, Spain (I.B., M.V., E.G., J.C.); Department of Radiology, Vall d'Hebron University Hospital, Barcelona, Spain (M.E.); Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain (R.T.); Department of Physiology and Medical Physics, Centre for Systems Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland (A.T.B.); and National Pre-clinical Imaging Centre, Dublin, Ireland (A.T.B.).

Publikováno v: Radiology. Artificial intelligence [Radiol Artif Intell] 2024 Mar; Vol. 6 (2), pp. e230118.

1063P Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors

Autor: Tozzi, C., Ligero, M., Antolin, A., Atlagich, L.M., Staikoglou, N., Bernatowicz, K., Vieito Villar, M., Alonso, G., Galvao, V., Braña, I., Oberoi, A., Saavedra Santa Gadea, O., Muñoz Couselo, E., Garralda, E., Perez Lopez, R.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S642-S643

First families with spinocerebellar ataxia type 7 in Poland.

Autor: Dulski J; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.; Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.; Neurology Department, St Adalbert Hospital, Copernicus PL Ltd., Gdansk, Poland., Al-Shaikh RH; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA.; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States., Prudencio M; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States.; Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, Florida, United States., Petrucelli L; Department of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States.; Mayo Clinic Graduate School of Biomedical Sciences, Jacksonville, Florida, United States., Sulek A; Faculty of Medicine, Lazarski University, Warsaw, Poland., Bernatowicz K; Department of Genetics, Pomeranian Medical University in Szczecin, Szczecin, Poland., Sławek J; Division of Neurological and Psychiatric Nursing, Faculty of Health Sciences, Medical University of Gdansk, Gdansk, Poland.; Neurology Department, St Adalbert Hospital, Copernicus PL Ltd., Gdansk, Poland., Wszolek ZK; Department of Neurology, Mayo Clinic, Jacksonville, Florida, USA. wszolek.zbigniew@mayo.edu.

Publikováno v: Neurologia i neurochirurgia polska [Neurol Neurochir Pol] 2023; Vol. 57 (3), pp. 310-313. Date of Electronic Publication: 2023 Jun 07.

196 (PB076) - Non-invasive biomarkers for response and survival prediction in patients with advanced solid tumours treated with immune checkpoint inhibitors (ICIs)

Autor: Bernatowicz, K., Vieito, M., Berche, R., Alonso, G., Galvao, V., Oberoi, H.K., Braña, I., Saavedra, O., Muñoz-Couselo, E., Grussu, F., Belen, A., Serna, G., Rotxes, M., Sanz, M., Tabernero, J., Toledo, R., Nuciforo, P., Garralda, E., Perez-Lopez, R.

Publikováno v: In European Journal of Cancer October 2022 174 Supplement 1:S70-S70